Search filters

Filters
Clear All

Phase

  • 4
  • 9
  • 14
  • 2
  • 5
  • 36
  • 17
  • 1
  • 35
  • 35
  • 1

Found 36 Lymphoma trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
We would like to rely on the WIRB as IRB of record for this study. The main purpose of this study is to find out if the investigational therapy tisagenlecleucel (i.e. CTL019, CART-19, or Kymriah®) is safe and has beneficial effects in people who have relapsed or refractory aggressive B-cell …
18 years - 99 years
All genders
Phase 2
Interventional
The research study is being conducted to test the safety and efficacy of SGX301 (an investigational drug) in patients with mycosis fungoides in combination with light therapy using standard fluorescent lights. Eligible participants must have been diagnosed with mycosis fungoides, a form of Cutaneous T-cell Lymphoma. Participants will be asked …
99 years or below
All genders
Phase 1
Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints)
99 years or below
All genders
The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.
 RADVAX FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: A PHASE II TRIAL OF PEMBROLIZUMAB + LOW DOSE RADIOTHERAPY
18 years - 99 years
All genders
Phase 2
This study plans to treat subjects with pembrolizumab by infusion in combination with radiation therapy to see if the combination is an effective treatment for relapsed/refractory non-Hodgkin lymphoma. Radiation therapy is commonly used to treat relapsed/refractory non-Hodgkin lymphoma. Although pembrolizumab is FDA-approved for some cancers, including Hodgkin lymphoma, it is …
99 years or below
All genders
Phase 2
The purpose of this study is to determine the safety and tolerability of pembrolizumab in people with lymphoma whose lymphoma relapsed or did not respond after receiving at least one prior treatment for lymphoma. This study will also determine how well patients with lymphoma respond to pembrolizumab.
 UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
18 years - 64 years
All genders
Phase 1
Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).  
18 years - 99 years
All genders
Phase 2
Please refer to Section 2 of the full protocol (Study Objectives). Please refer to Section 8.1 of the full protocol (Study Endpoints). Please refer to Section 8.1 of the full protocol (Study Endpoints).
 Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma
18 years - 99 years
All genders
Patients with plasmablastic lymphoma are potential participants of this research trial. Patients with a type of B-cell non-Hodgkin lymphoma (NHL) will be invited from Penn Medicine practices. This research study is designed to test the safety of daratumumab, a drug added to the standard lymphoma treatment when given to individuals …
99 years or below
All genders
Lymphoma survivors who were treated with prior radiation therapy have been shown to have an increased risk of cancers of the gastrointestinal system. This increased cancer risk may be due to damage to cells in your gastrointestinal system that is caused at the time of radiation. This research is being …
11 - 20 of 36